EGFR and cancer: Whether it is well-acknowledged that actionable mutations in the driver oncogenes epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) confer resistance to ICI [60,61], accumulating evidence suggests a possible positive or negative predictive role for other tumor mutations, involved in various cancer pathways, that may improve the predictive ability of both PD-L1 and TMB when combined.